Category: Uncategorized

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

March 5, 2025

Read More
Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

January 28, 2025

Read More
Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

January 14, 2025

Read More
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

January 13, 2025

Read More